scholarly journals Serum Myeloperoxidase Level Is Associated with Heart-Type Fatty Acid-Binding Protein but Not Troponin T in Patients with Chronic Heart Failure

2014 ◽  
Vol 24 (1) ◽  
pp. 42-46 ◽  
Author(s):  
Omer Gedikli ◽  
Abdulkadir Kiris ◽  
Yusuf Hosoglu ◽  
Caner Karahan ◽  
Sahin Kaplan
Keyword(s):  
Heart Failure ◽  
Fatty Acid ◽  
Chronic Heart Failure ◽  
Fatty Acid Binding Protein ◽  
Troponin T ◽  
Binding Protein ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

scholarly journals Elevated Heart-Type Fatty Acid-Binding Protein Predicts Early Myocardial Injury and Aids in the Diagnosis of Non-St Elevation Myocardial Infarction

2009 ◽  
Vol 16 (3) ◽  
pp. 141-147 ◽  
Author(s):  
GY Naroo ◽  
S Mohamed Ali ◽  
V Butros ◽  
A Al Haj ◽  
I Mohammed ◽  
...  
Keyword(s):  
Myocardial Infarction ◽  
Acute Coronary Syndrome ◽  
Fatty Acid ◽  
Chest Pain ◽  
Fatty Acid Binding Protein ◽  
Troponin T ◽  
Binding Protein ◽  
Fatty Acid Binding ◽  
Coronary Syndrome ◽  
Acid Binding Protein

Background Biomarkers play an important role in the early diagnosis, risk stratification and management of patients with the acute coronary syndrome. Objective The objective of this study was to evaluate the clinical reliability of heart-type fatty acid-binding protein (h-FABP) in identifying patients with the acute coronary syndrome in the early hours of chest pain. Methods Creatine kinase (CK-MB) (in laboratory), troponin T (in laboratory) and h-FABP (with point-of-care test CardioDetect®) were performed on 791 patients who presented with chest pain with duration since onset ranging from 20 minutes to 12 hours. Results Data of the 791 patients were analysed. h-FABP had a higher sensitivity of 75.76% and a specificity of 96.97% compared with 58.59% and 98.84% for troponin T and 68.69% and 97.54% for CK-MB respectively (in the first 6 hours). Conclusion: h-FABP was found to be a better biomarker of cardiac necrosis in the early hours in the diagnosis of non-conclusive ECG in patients with acute myocardial infarction. (Hong Kong j.emerg.med. 2009;16:141–147)

scholarly journals Role of the fatty acid-binding protein 4 in heart failure and cardiovascular disease

2017 ◽  
Vol 233 (3) ◽  
pp. R173-R184 ◽  
Author(s):  
Ricardo Rodríguez-Calvo ◽  
Josefa Girona ◽  
Josep M Alegret ◽  
Alba Bosquet ◽  
Daiana Ibarretxe ◽  
...  
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Fatty Acid ◽  
Fatty Acid Binding Protein ◽  
Binding Protein ◽  
Left Ventricular ◽  
Aetiological Factor ◽  
Fatty Acid Binding ◽  
Acid Binding Protein

Obesity and ectopic fat accumulation in non-adipose tissues are major contributors to heart failure (HF) and cardiovascular disease (CVD). Adipocytes act as endocrine organs by releasing a large number of bioactive molecules into the bloodstream, which participate in a communication network between white adipose tissue and other organs, including the heart. Among these molecules, fatty acid-binding protein 4 (FABP4) has recently been shown to increase cardiometabolic risk. Both clinical and experimental evidence have identified FABP4 as a relevant player in atherosclerosis and coronary artery disease, and it has been directly related to cardiac alterations such as left ventricular hypertrophy (LVH) and both systolic and diastolic cardiac dysfunction. The available interventional studies preclude the establishment of a direct causal role of this molecule in CVD and HF and propose FABP4 as a biomarker rather than as an aetiological factor. However, several experimental reports have suggested that FABP4 may act as a direct contributor to cardiac metabolism and physiopathology, and the pharmacological targeting of FABP4 may restore some of the metabolic alterations that are conducive to CVD and HF. Here, we review the current knowledge regarding FABP4 in the context of HF and CVD as well as the molecular basis by which this protein participates in the regulation of cardiac function.

Sign in / Sign up

Export Citation Format

Share Document